ARCHIVES

FDA Committee Agenda Includes M-AMSA, THC, Estramustine, Platinum

This article is from The Cancer Letter archive.

Vol. 07 No. 21 | May 22, 1981

Download PDF Visit The Full Archive

Related Articles

BRCA 1 Mutation Finding Draws Attention To Potential Perils Of Genetic Testing

October 6, 1995

OHSU Get $500 Million Pledge; Funds to be Matched in Two Years

September 27, 2013

Surgery Without Radiation Found Inadequate for DCIS

December 26, 2003

NCI Will Encourage More Activity In Environment Carcinogenesis

June 21, 1974

NCI Largely Unaffected By NIH Translational Research Center

February 11, 2011

Public Participation Hearings Develop Gals for Reducing Cancer Mortality

February 17, 1989